Serum Sclerostin in Alcoholics: A Pilot Study | Zendy

Emilio GonzálezReimers | Zendy; Candelaria MartínGonzález | Zendy; Marı́a José de la Vega-Prieto | Zendy; Ricardo Pelazas-González | Zendy; C. Fernández-Rodríguez | Zendy; J. López-Prieto | Zendy; J. Alvisa-Negrín | Zendy; F. Santolaria-Fernández | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum Sclerostin in Alcoholics: A Pilot Study

Author(s) -

Emilio GonzálezReimers,

Candelaria MartínGonzález,

Marı́a José de la Vega-Prieto,

Ricardo Pelazas-González,

C. Fernández-Rodríguez,

J. López-Prieto,

J. Alvisa-Negrín,

F. Santolaria-Fernández

Publication year - 2013

Publication title -

alcohol and alcoholism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 99

eISSN - 1464-3502

pISSN - 0735-0414

DOI - 10.1093/alcalc/ags136

Subject(s) - sclerostin , medicine , endocrinology , osteocalcin , bone remodeling , n terminal telopeptide , bone mineral , osteoporosis , osteopontin , osteoblast , alkaline phosphatase , chemistry , wnt signaling pathway , biochemistry , in vitro , gene , enzyme

Sclerostin is an endogenous inhibitor of the Wnt/β-catenin pathway secreted by osteocytes, which inhibits osteoblast function, differentiation and survival. As a consequence, sclerostin tends to decrease bone mass. Alcoholics frequently present osteoporosis, mainly due to decreased bone synthesis. The behaviour of sclerostin in these patients is unknown. The aim of this work was to analyse the relationship between serum sclerostin levels and bone mineral density (BMD), ethanol consumption, nutritional status, liver function derangement and biomarkers of bone homeostasis in alcoholic patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research